In an Oct. 6 research note, Selvaraju reported that the New England Journal of Medicine published the results from Inovio Pharmaceuticals Inc.'s (INO:NASDAQ) "first Phase 1 trial in humans of DNA-based Zika vaccine (GLS-5700)."
Selvaraju concluded the trial outcomes "demonstrate GLS-5700's potential efficacy in preventing Zika virus infection in humans together with a solid safety profile and bode well for the potential data readout from the second human trial around mid-2018."
In this Phase 1 study, 20 subjects received 1 mg and 20 subjects received 2 mg of GLS-5700 intradermally, Selvaraju wrote. The vaccine "induced high levels of binding antibodies in all participants after a three-dose vaccination regimen at 14 weeks," he noted, adding "neutralizing antibodies developed in 62% of the samples on Vero-cell assay."
Further, the analyst wrote, "On neuronal-cell assay, there was 90% inhibition of Zika virus infection in 70% of the serum samples and 50% inhibition in 95% of the samples. No serious adverse events were observed."
Inovio's second trial involving its Zika vaccine, another Phase 1 study (ZIKA-002), is already underway. Enrollment of 160 adults in Puerto Rico is complete. "This is a randomized, placebo-controlled, double-blind trial with 80 subjects receiving vaccine and 80 receiving placebo, designed to explore a potential trend toward clinical efficacy," Selvaraju explained.
In an Oct. 17 research report, Selvaraju commented on the initiation of a "Phase 1b/2 immuno-oncology trial in advanced bladder cancer" with a combination of INO-5401, INO-9012 and Tecentriq, produced by Genentech/Roche Holding AG (RHHBY:OTCQX).
"Approximately 80 patients with advanced unresectable or metastatic urothelial carcinoma (UC) are slated to be enrolled, the majority of whom would have previously received and failed to respond to an anti-PD-1 or PD-L1 checkpoint inhibitor alone," Selvaraju wrote. "The combination of checkpoint inhibition and [Inovio's] T cell activation could improve the response rate in this patient group, who have limited treatment options."
The analyst also noted that, "If T cell activators can indeed deliver a synergistic therapeutic effect with checkpoint inhibitors, this could immensely improve clinical outcomes by prolonging survival in patients with metastatic disease, in our view."
Near term for Inovio, another of its drug candidates, VGX-3100 for treatment of cervical dysplasia, is in enrollment for the Phase 3 REVEAL 1 trial, which is expected to begin in Q4/17. "Each study is slated to enroll 198 patients in over 100 centers globally," wrote Selvaraju.
H.C. Wainwright reiterates its Buy rating and $13 per share price target on Inovio, whose stock is currently trading at around $6.25 per share.
Read what other experts are saying about:
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) Tracy Salcedo contributed to this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
3) The following company mentioned in this article is a sponsor of Streetwise Reports: Inovio Pharmaceuticals Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
6) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
H.C. Wainwright & Co., Inovio Pharmaceuticals Inc., Company Update, Oct. 6, 2016 and Oct. 17, 2017
I, Raghuram Selvaraju, Ph.D. and Yi Chen, Ph.D. CFA , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
None of the research analysts or the research analyst’s household has a financial interest in the securities of Inovio Pharmaceuticals, Inc. (including, without limitation, any option, right, warrant, future, long or short position).
As of September 30, 2017 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Inovio Pharmaceuticals, Inc.
Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.
The Firm or its affiliates did receive compensation from Inovio Pharmaceuticals, Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
The Firm does not make a market in Inovio Pharmaceuticals, Inc. as of the date of this research report.